Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurol Sci ; 149(1): 19-25, 1997 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9168161

RESUMO

Zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) are the reference antiretroviral therapy in patients with AIDS. A toxic mitochondrial myopathy can be observed in patients treated with AZT, but not with ddI and ddC. All 3 compounds can inhibit mitochondrial (mt)DNA polymerase and cause termination of synthesis of growing mtDNA strands and mtDNA depletion. The propensity to injure particular target tissues is unexplained. In our work, cultured muscle cells prepared from human muscle biopsies, were exposed to various concentrations of AZT (4-5000 micromol/l), ddI (5-1000 micromol/l) and ddC (1-1000 micromol/l) for 10 days. We evaluated cell proliferation and differentiation and measured lipid droplet accumulation, lactate production and respiratory chain enzyme activities. All 3 compounds induced a dose-related decrease of cell proliferation and differentiation. AZT seemed to be the most potent inhibitor of cell proliferation. AZT, ddI and ddC induced cytoplasmic lipid droplet accumulations, increased lactate production and decreased activities of COX (complex IV) and SDH (part of complex II). NADHR (complex I) and citrate sinthase activities were unchanged. Zalcitabine (ddC) and, to a lesser extent, ddI, were the most potent inhibitors of mitochondrial function. In conclusion, AZT, ddI and ddC all exert cytotoxic effects on human muscle cells and induce functional alterations of mitochondria possibly due to mechanisms other than the sole mtDNA depletion. Our results provide only a partial explanation of the fact that AZT, but not ddI and ddC, can induce a myopathy in HIV-infected patients. AZT myopathy might not simply result from a direct mitochondrial toxic effect of crude AZT.


Assuntos
Fármacos Anti-HIV/toxicidade , Didanosina/toxicidade , Mitocôndrias Musculares/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Zalcitabina/toxicidade , Zidovudina/toxicidade , Biópsia , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Células Cultivadas , DNA Mitocondrial/biossíntese , Relação Dose-Resposta a Droga , Complexo II de Transporte de Elétrons , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Cinética , Lactatos/metabolismo , Metabolismo dos Lipídeos , Mitocôndrias Musculares/metabolismo , Complexos Multienzimáticos/metabolismo , Músculo Esquelético/citologia , Músculo Esquelético/metabolismo , NAD(P)H Desidrogenase (Quinona)/metabolismo , Inibidores da Síntese de Ácido Nucleico , Oxirredutases/metabolismo , Succinato Desidrogenase/metabolismo
2.
Br J Clin Pharmacol ; 42(3): 333-7, 1996 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8877024

RESUMO

1. Statins inhibit synthesis of mevalonate, a precursor of ubiquinone that is a central compound of the mitochondrial respiratory chain. The main adverse effect of statins is a toxic myopathy possibly related to mitochondrial dysfunction. 2. This study was designed to evaluate the effect of lipid-lowering drugs on ubiquinone (coenzyme Q10) serum level and on mitochondrial function assessed by blood lactate/pyruvate ratio. 3. Eighty hypercholesterolaemic patients (40 treated by statins, 20 treated by fibrates, and 20 untreated patients, all 80 having total cholesterol levels > 6.0 mmol l-1) and 20 healthy controls were included. Ubiquinone serum level and blood lactate/pyruvate ratio used as a test for mitochondrial dysfunction were evaluated in all subjects. 4. Lactate/pyruvate ratios were significantly higher in patients treated by statins than in untreated hypercholesterolaemic patients or in healthy controls (P < 0.05 and P < 0.001). The difference was not significant between fibratetreated patients and untreated patients. 5. Ubiquinone serum levels were lower in statin-treated patients (0.75 mg l-1 +/- 0.04) than in untreated hypercholesterolaemic patients (0.95 mg l-1 +/- 0.09; P < 0.05). 6. We conclude that statin therapy can be associated with high blood lactate/ pyruvate ratio suggestive of mitochondrial dysfunction. It is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction.


Assuntos
Inibidores Enzimáticos/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases , Hipolipemiantes/efeitos adversos , Ácido Láctico/sangue , Mitocôndrias/efeitos dos fármacos , Ácido Pirúvico/sangue , Ubiquinona/sangue , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
3.
Arch Pathol Lab Med ; 118(7): 695-7, 1994 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8024401

RESUMO

Blood lactate and pyruvate are of critical importance for the diagnosis of mitochondrial diseases. To determine guidelines for adequate blood pyruvate and lactate determinations, intraindividual studies were carried out on 10 subjects, and the influences of venostasis, delay before deproteinization, and pH in the pyruvate assay were analyzed. Delays of 1 hour or more before deproteinization of samples induced major elevations of lactate-pyruvate ratios. The lactate-pyruvate ratio correlated positively with pH in the pyruvate assay, and inadequate pH appeared as a largely underestimated cause of misleading results, while venostasis was a minor source of errors.


Assuntos
Coleta de Amostras Sanguíneas/normas , Lactatos/sangue , Piruvatos/sangue , Adulto , Feminino , Humanos , Concentração de Íons de Hidrogênio , Ácido Láctico , Masculino , Pessoa de Meia-Idade , Ácido Pirúvico , Reprodutibilidade dos Testes , Temperatura , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...